Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 32,2022 No.2Detail

Interpretation of the clinical pathway for transurethral plasmakinetic resection of bladder tumor

Published on Apr. 25, 2022Total Views: 19652 timesTotal Downloads: 5760 timesDownloadMobile

Author: Si-Yu YAN 1 Xing HUANG 1, 2 Zheng CHEN 3 Lu YANG 4 Zhao-Hui JIA 5 Mou PENG 6 Xuan-Yi REN 7 Jing XIONG 8 Xiao-Dong LI 9 Xiao-Feng XU 10 Yong-Bo WANG 1 Xu-Hui LI 1 Hang ZHENG 2 Ting WANG 2 Ying-Hui JIN 1 Hao ZI 1, 2 Tong-Zu LIU 2 Xian-Tao ZENG 1, 2 Da-Lin HE 11 Xing-Huan WANG 2 Urology Professional Committee of Chinese Research Hospital Associa-tion Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care Project Group for Minimally Invasive Plasmakinetic Surgery System Development and Industrial-ization of the National Key Research and Development Program

Affiliation: 1. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 3. Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China 4. Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China 5. Department of Urology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, Henan Province, China 6. Department of Urology, The Second Xiangya Hospital, Central South University, Changsha 410011, China 7. Department of Urology, Kaifeng Central Hospital, Kaifeng 475001, Henan Province, China 8. De-partment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China 9. Department of Urology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China 10. Department of Urol-ogy, Xianyang Central Hospital, Xianyang 712000, Shaanxi Province, China 11. Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China

Keywords: Clinical pathway Bladder tumor Non-muscle invasive bladder cancer Transurethral plasmakinetic resection Plasma bipolar resection Evidence-based medicine

DOI: 10.12173/j.issn.1004-5511.202204022

Reference: Yan SY, Huang X, Chen Z, YANG L, Jia ZH, Peng M, Ren XY, Xiong J, Li XD, Xu XF, Wang YB, Li XH, Zheng H, Wang T, Jin YH, Zi H, Liu TZ, Zeng XT, He DL, Wang XH, Urology Professional Committee of Chinese Research Hospital Association, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care, Project Group for Minimally Invasive Plasmakinetic Surgery System Development and Industrialization of the National Key Research and Development Program. Interpretation of the clinical pathway for transurethral plasmakinetic resection of bladder tumor[J]. Yixue Xinzhi Zazhi, 2022, 32(2): 81-89. DOI: 10.12173/j.issn.1004-5511.202204022.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Bladder cancer is the tenth most frequently diagnosed cancer in the world, and is more common among men. Transurethral resection of bladder tumor is not only an important diagnostic method for bladder tumors, but also a major treatment for non-muscle invasive bladder cancer. Com-pared with traditional unipolar electrotomy, plasma bipolar electrotomy has the advantages of good surgical results and fewer complications, and its clinical application is becoming more and more exten-sive. In order to standardize the diagnosis and treatment of common diseases, the National Health Commission continues to issue relevant clinical pathways; however, the content of a clinical pathway is limited, and its interpretation can help it be better disseminated and used. This interpretation is based on the latest "clinical pathway for transurethral plasma resection of bladder tumor (2019 edition)". It uses the method of evidence-based medicine to make a detailed and necessary supplementary descrip-tion of the pathway, and gives a detailed interpretation of the drug delivery scheme involved, so as to provide reference for medical staff and managers to better understand, grasp and correctly use it.

Full-text
Please download the PDF version to read the full text: download
References

1.Sung H, Ferlay J, Siegel RL, et al. Estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

2.Zi H, He SH, Leng XY, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019[J]. Mil Med Res, 2021, 8(1): 60. DOI: 10.1186/s40779-021-00354-z.

3.訾豪, 彭谋, 王江宜, 等. 1990~2017年中国膀胱癌疾病负担分析[J]. 医学新知, 2020, 30(5): 328-335. [Zi H, Peng M, Wang JY, et al. An analysis of disease burden of bladder cancer in China from 1990 to 2017[J]. Yixue Xinzhi Zazhi, 2020, 30(5): 328-335.] DOI: 10.12173/j.issn.1004-5511.2020.05.01.

4.EAU Guideline. Non-muscle-invasive Bladder Cancer[EB/OL]. [2022-03-28]. https://uroweb.org/guideline/non-muscle-inva sive-bladder-cancer/.

5.王行环. 经尿道前列腺等离子双极电切术[J]. 医学新知, 2004, 14(1): 8-9. [Wang XH. Transurethral plas-makinetic resectic:treatment benign prostatic hyperplasia[J]. Yixue Xinzhi Zazhi, 2004, 14(1): 8-9.] DOI: 10.3969/j.issn.1004- 5511.2004.01.004.

6.中国医疗保健国际交流促进会泌尿健康促进分会，中国研究型医院学会泌尿外科学专业委员会，国家重点研发计划微创等离子手术体系及云规划解决方案项目组.经尿道膀胱肿瘤等离子电切安全共识[J]. 现代泌尿外科杂志, 2018, 23(12): 895-901. [Uro-Health Promotive Association of China International Exchange and Promotive Association for Medical and Health Care (CPAM-UHPA), Urological Association of Chinese Research Hospital Association (CRHA-UA), Project Group for Minimally Invasive Plasmakinetic Surgery System Development and Industrialization of the National Key Research and Development Program. Consen-sus on the safety of transurethral plasma resection of bladder tumors[J]. Journal of Modern Urology, 2018, 23(12): 895-901.] DOI: 10.3969/j.issn.1009-8291.2018.12.003.

7.曾宪涛, 冯佳佳, 蔡广研, 等. 制定/修订《临床路径释义》的基本方法与程序(2020年更新版)[J].中国研究型医院, 2020, 7(2): 65-68. [Zeng XT, Feng JJ, Cai GY, et al. The methods and procedures of formulating and re-vising the interpretation of clinical pathway (2020 update)[J]. Journal of Chinese Research Hospitals, 2020, 7(2): 65-68.] DOI: 10.19450/j.cnki.jcrh. 2020.02.014.

8.中华人民共和国国家卫生健康委员会. 国家卫生健康委办公厅关于印发有关病种临床路径（2019年版）的通知[EB/OL]. (2020-01-02) [2022-03-28]. http://www.nhc.gov.cn/yzygj/s7659/202001/b3c9e097b0c1471a969d7 a63be471759.shtml.

9.周利群，王行环. 临床路径释义（泌尿外科分册）[M].北京：中国协和医科大学出版社, 2018. [Zhou LQ, Wang XH. In-terpretation of Clinical Pathway[M]. Beijing: Peking Union Medical College Press, 2018.]

10.中国研究型医院学会泌尿外科学专业委员会, 中国医疗保健国际交流促进会泌尿健康促进分会, 中国医疗保健国际交流促进会循证医学分会, 等. 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018简化版)[J].中国循证医学杂志, 2018, 18(12): 1267-1272. [Urological Association of Chinese Research Hospital Association (CRHA-UA), Urinary Health Promotion Branch of China Medical and Healthcare International Exchange Promotion Association, Uro-Health Promotive Association of China International Exchange and Pro-motive Association for Medical and Health Care (CPAM-UHPA). Treatment and surveillance for non-muscle-invasive bladder cancer in China: an evidence-based clinical practice guideline (2018 sim-plified version)[J]. Chinese Journal of Evidence-Based Medicine, 2018, 18(12): 1267-1272.] DOI: 10.7507/1672-2531.201812031.

11.靳英辉, 曾宪涛. 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018年标准版)[J].现代泌尿外科杂志, 2019, 24(7): 516-542. [Jin YH, Zeng XT. Evidence-based clinical practice guidelines for the treatment and monitoring of non-muscle invasive bladder cancer in China (2018 standard edition)[J]. Journal of Modern Urology, 2019, 24(7): 516-542.] DOI: 10.3969/j.issn.1009-8291.2019.07.004.

12.Jin YH, Zeng XT, Liu TZ, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 primary medical institution's version)[J]. Mil Med Res, 2022, 9(1): in press.

13.黄健. 中国泌尿外科和男科疾病诊断治疗指南（2019版）[M]. 北京：科学出版社, 2020. [Huang J. Guidelines for diagnosis and treatment of urology and andrology in China (2019 Edition)[M]. Beijing: Science Press, 2020.]

14.European Association of Urology. EAU guideline on management of non-neurogenic male LUTS[EB/OL]. (2022) [2022-03-28]. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/.

15.European Association of Urology. EAU Guideline: Muscle-invasive and Metastatic Bladder Can-cer[EB/OL]. (2022) [2022-03-28]. https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer.

16.American Urological Association. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline (2020)[EB/OL]. (2020) [2022-03-28]. https://www.auanet.org/guidelines/guidelines/bladder-cancer-non-muscle-invasive- guideline.

17.国家卫生计生委办公厅，国家中医药管理局办公室和解放军总后勤部卫生部药品器材局. 关于印发抗菌药物临床应用指导原则（2015年版）的通知（国卫办医发[2015]43号附件）[EB/OL]. (2015) [2022-03-28]. http://www.gov.cn/xinwen/2015-08/27/content_2920799.htm.

18.张恺, 鄢祺, 阮善明. 中药联合膀胱灌注治疗非肌层浸润性膀胱癌根治术后Meta分析[J].浙江中西医结合杂志, 2020, 30(7): 589-595. [Zhang K, Yan Q, Ruan SM. Meta-analysis of traditional Chinese medicine combined with intravesical instillation in the treatment of non-muscle invasive bladder cancer after radical resec-tion[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 2020, 30(7): 589-595.] DOI: 10.3969/j.issn.1005-4561.2020.07.021.

19.罗松涛, 戟美英, 韩立, 等. 中医药对膀胱癌术后灌注化疗减毒增效的临床研究[J].中国当代医药, 2016, 23(3): 93-95. [Luo ST, Ji MY, Han L, et al. Clinical study of traditional Chinese medicine on toxicity reducing and ef-ficacy enhancing of infusion chemotherapy after bladder cancer surgery[J]. Chinese contemporary medicine, 2016, 23(3): 93-95.] DOI: CNKI:SUN:ZGUD.0.2016-03-030.

Popular Papers
© 2022 - 2026 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us